Astragaloside Iv for Wound Healing

Research suggests that astragaloside IV may support wound healing through multiple complementary mechanisms, including promoting skin cell migration and proliferation, stimulating new blood vessel formation, enhancing collagen deposition, modulating inflammation, and potentially limiting excessive scar formation. Studies indicate these effects operate through identifiable molecular pathways, such as PI3K/AKT/mTOR, GSK-3β/Nrf2, and H19/ILF3/CDK4 signaling, and the compound has also shown promise when incorporated into advanced delivery systems such as nanofiber dressings, liposomal formulations, and hydrogel-based nanoparticles designed to improve its bioavailability and sustained release at the wound site. The available evidence comes predominantly from animal models and cell culture experiments, with several studies focusing specifically on the impaired healing environment characteristic of diabetes, and one 2026 review confirms that while the overall picture from preclinical research is consistently supportive, human clinical trial data remain absent. This gap between laboratory findings and clinical validation means that, despite a coherent and growing body of mechanistic and animal evidence, conclusions about efficacy in humans cannot yet be drawn.